Treatment of IGA nephropathy of adults presented bynephrotic syndrome

Bosnian Journal of Basic Medical Sciences

Volumn 8, Issue 3, 2008, Pages 230-233

  Rašic, Senija ^a   Uncanin, Snježana ^a   Aganovic, Kenana ^a   Rašic, Ismar ^a   Džemidžic, Jasminka ^a   Muslimovic, Alma ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

IgA nephropathy; Nephrotic syndrome; Outcome; Treatment

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BIOPSY; DOSE RESPONSE; DRUG COMBINATION; DRUG PULSE THERAPY; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; BIOPSY; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 54549111489     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2008.2923     Document Type: Article

References (13)

1. Nishi S. The prognosis of IgA nephropathy - favorable or poor? Intern. Med. 2001; 40:679-680.
2. Koyama A., Igarashi M., Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am. J. Kidney Dis. 1997; 29:526-532.
3. Schena F.P. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am. J. Med. 1990; 89:209-215.
4. Lee S.M.K., Rao V.M., Franklin W.A., Schiffer M.S., Aronson A.J., Spargo B.H, Katz A.I. IgA nephropathy: Morphologic predictors of progressive renal disease. Hum. Pathol. 1982; 13:314-322.
5. Haas M. Histological subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am. J. Kidney Dis. 1997; 29(6):829-842.
6. Hass M. IgA nephropathy histologically resembling focal-seg-mental glomerulosclerosis: A clinicopathologic study of 18 cases. Am. J. Kidney Dis. 1996; 28:365-371.
7. Nolin L., Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int. Suppl. 1999; 70:S56-S62.
8. Pozzi C., Andrulli S., Del Vecchio L., Melis P., Fogazzi G.B., Altieri P., Ponticelli C., Locatelli F. Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial. J. Am. Soc. Nephrol. 2004; 15:157-163.
9. Ballardie F.W., Roberts I.S. Controlled prospective trial of pred-nisolone and cytotoxics in progressive IgA nephropathy. J. Am. Soc. Nephrol. 2002; 13:142-148.
10. Katafuchi R., Ikeda K., Mizamasa T., Tanaka H., Ando T., Yanase T., Masutan K., Kubo M., Fujimi S. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am. J. Kidney Dis. 2003; 41:972-983.
11. Cappo R., Amore A. New perspectives in treatment of glomeru-lonephritis. Pediatr. Nephrol. 2004; 19:256-265.
12. Hruby Z. What is new in therapy of glomerulonephritis in the 2003/2004. Rocz. Akad. Med. Bialymst. 2004:49:166-169.
13. Tang S., Leung J.C., Chan L.Y., Lui U.H., Tang C.S., Kan C.H., Ho Y.W., Lai K.N. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005; 68(2):802-812.